The expansion supports CoSara’s plans to commercialise its PCR Pro and Saragene products.

Austin, United States, March 09, 2026 (GLOBE NEWSWIRE) -- Point-of-Care Molecular Diagnostics Market Size & Growth Analysis: According to SNS Insider, The Point-of-Care Molecular Diagnostics Market ...

In the following sections, we highlight ethical concerns about early adoption of molecular diagnostic testing without solid evidence or guidelines and offer practical guidance for ethical ...

When Domain Associates led Xagenic Inc.’s recent $20 million Series B, it marked the eighth diagnostics investment the firm had made with its $500 million eighth fund. The partners say they’ve ...

CODX (NASDAQ:CODX) is making a strategic push to scale its global diagnostics platform, announcing a major expansion of ...

In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market.

IMDX is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of IMDX shares has decreased $0.10 since the market last closed. This is a 1.74% ...

As the Centers for Medicare and Medicaid Services calls for public feedback on how to stop lab test fraud, experts say a tailored regulatory strategy will be key to avoid stifling innovation.

The dangers for infection aren’t only caused by microbes, but also by the molecular signals they release. To detect and neutralize these signals, may be the next era for infectious disease control.” — ...